Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.
Roehrborn
Claus G
CG
Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. clausroehrborn@utsouthwestern.edu
Lotan
Yair
Y
Tubaro
Andrea
A
de Nunzio
Cosimo
C
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism; D058891:5-alpha Reductase Inhibitors; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018890:Chemoprevention; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011322:Primary Prevention; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000453:epidemiology / Q000517:prevention & control*; D047368:Tumor Burden / Q000187:drug effects; D014481:United States / Q000453:epidemiology
D058891:5-alpha Reductase Inhibitors; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase